Results 181 to 190 of about 5,351,550 (365)

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway

Journal of Pharmaceutical Policy and Practice
Background Withdrawals of drug indications may reveal potential inadequacies in the regulatory approval processes of new drugs. Understanding potential weaknesses of the regulatory approval process is paramount given the increasing use of expedited ...
Mahnum Shahzad, Huseyin Naci, Katharine M. Esselen, Joseph A. Dottino, Anita K. Wagner   +4 more
doaj   +1 more source

Implications of Evolving Disease Classification for Drug Approval in Juvenile Idiopathic Arthritis. [PDF]

Paediatr Drugs, 2022
Case SM, Nigrovic PA.
europepmc   +1 more source

Boosting drug-disease association prediction for drug repositioning via dual-feature extraction and cross-dual-domain decoding [PDF]

arXiv
The extraction of biomedical data has significant academic and practical value in contemporary biomedical sciences. In recent years, drug repositioning, a cost-effective strategy for drug development by discovering new indications for approved drugs, has gained increasing attention.
arxiv  

Potential conflict between fundamental ethical principles and requirements of the oncology drug approval process [PDF]

, 2003
Maurie Markman, Joseph DeMarco
openalex   +1 more source

Supreme Court Amicus Brief Regarding Wyeth v. Diana Levine [PDF]

Prominent in arguments opposing preemption of state tort law liability for alleged inadequacies in prescription drug labeling is the argument that such liability can complement FDA regulation by improving on a regulatory scheme that fails to provide ...
Berndt, Ernst R., Calfee, John E., Hahn, Robert W., Philipson, Tomas J., Rubin, Paul H., Viscusi, W. Kip   +5 more
core   +1 more source

Clinical Trial 2.0: Can Health 2.0 Transform the FDA Drug Approval Process? [PDF]

, 2012
Historically, patient activism has played a great part in shaping the drug approval process. Today, aided by developing web technologies, patients are once again seeking increased involvement in their medical care.
Atanassova, Mira
core  

Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles

Molecular Oncology, EarlyView.
Breast cancer metastasis is associated with myeloid cell dysregulation and the lung‐specific accumulation of tumor‐supportive Gr1+ cells. Gr1+ cells support metastasis, in part, through a CHI3L1‐mediated mechanism, which can be targeted and inhibited with cargo‐free, polymeric nanoparticles.
Jeffrey A. Ma, Sophia M. Orbach, Kate V. Griffin, Kathryn Kang, Yining Zhang, Rebecca S. Pereles, Ian A. Schrack, Guillermo Escalona, Jacqueline S. Jeruss, Lonnie D. Shea   +9 more
wiley   +1 more source

Current philosophical perspectives on drug approval in the real world

Journal of Causal Inference
The evidence-based medicine approach to causal medical inference is the dominant account among medical methodologists. Competing approaches originating in the philosophy of medicine seek to challenge this account.
Landes Jürgen, Auker-Howlett Daniel J.
doaj   +1 more source

Evergreening: A Common Practice to Protect New Drugs [PDF]

, 2012
Exclusivity periods serve as an incentive for pharmaceutical companies to engage in the costly and risky activities underlying drug discovery and development. Patents offer one form of exclusivity.
Gaudry, Katherine
core